Efficacy and Safety of Ticagrelor Compared with Clopidogrel in Patients with End-Stage Renal Disease with Acute Myocardial Infarction.
Chien-Ho LeeTzu-Hsien TsaiCheng-Jui LinShu-Kai HsuehWen-Jung ChungCheng-I ChengPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2019)
In patients with ESRD and AMI, ticagrelor resulted in numerically fewer but statistically nonsignificant rates of in-hospital and 1-year cardiovascular events with no significant increase in bleeding events compared with clopidogrel.
Keyphrases
- end stage renal disease
- percutaneous coronary intervention
- acute myocardial infarction
- cardiovascular events
- coronary artery disease
- chronic kidney disease
- peritoneal dialysis
- acute coronary syndrome
- antiplatelet therapy
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- atrial fibrillation
- cardiovascular disease
- healthcare
- acute care
- adverse drug
- heart failure
- type diabetes
- emergency department
- drug induced